A study published in Nature Cancer details how OCRA-funded research has dramatically expanded the impact of DNA and RNA data in the Cancer Genome Atlas and Cancer Cell Line Encyclopedia, … Continued
OCRA’s 2024 Mentored Investigator Grants are supporting fresh perspectives and approaches to end ovarian and related gynecologic cancers. This year’s grants are awarded to 5 exceptional young researchers who are … Continued
OCRA’s 2024 Early Career Investigator Grants are awarded to 8 outstanding young researchers with a strong commitment to ending ovarian and related gynecologic cancers. These grants fund innovative projects, and … Continued
OCRA’s Health Equity Research Grants for 2024 are dedicated to advancing equity in care of ovarian and related gynecologic cancers, addressing deep disparities in early diagnosis, access to care, and … Continued
Research breakthroughs are around the corner. In 2023, OCRA announced $9.2 million in research initiatives for 2024 — the largest in our history — including awarding 20 grants to scientists at … Continued
An OCRA research team is using Artificial Intelligence (AI) to develop a blood test to potentially detect ovarian cancer, as part of an OCRA-funded study in partnership with Microsoft AI … Continued
Snap Summary: OCRA-funded researchers discovered a potential key to reducing chemotherapy resistance, and reducing recurrence rates for the most common type of ovarian cancer. A research team at Magee-Women’s Research … Continued
Snap Summary: New findings could help develop better immune therapy for patients with the most common and lethal subtype of ovarian cancer. A recent study co-authored by Dr. Sherry Wu … Continued
Snap Summary: Research co-funded by OCRA found that foregoing genetic counseling before and after genetic testing does not negatively impact individuals who do not have a pathogenic mutation. Studies have … Continued
Snap Summary: An OCRA-funded study sought to understand why certain ovarian cancer cells resist olaparib treatment, and discovered that introducing a second drug (mifepristone) while targeting certain cells (polyploid giant … Continued
Snap summary: OCRA-funded researchers set out to improve immune response against a known therapeutic target, and provided a glimpse into a world where an ovarian cancer patient’s own immune system … Continued
A new study, published in the Journal of Clinical Investigation and funded in part by OCRA, has found that mesothelial cells are a critical factor in ovarian cancer metastasis. High-grade … Continued
Get email updates about research news, action alerts, and ways to join the fight.
